Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Andrew DeFilippis MD, MSc

Andrew P. DeFilippis MD, MSc

Associate Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, Medical Director, Cardiovascular Intensive Care, Vanderbilt University Medical Center, Nashville, TN

Dr. Andrew DeFilippis is a physician scientist with expertise in cohort development, clinical cardiology, cardiovascular epidemiology, bio-banking, biomarker development and identifying and differentiating specific types of myocardial injury, including all subtypes of myocardial infarction.

He graduated Georgetown University Medical School, completed his internal medicine residency and a Masters of Science in Clinical Research program at Emory University and Cardiovascular Fellowship at the Johns Hopkins Hospital.

He is a board-certified Cardiologist, Medical Director of the Vanderbilt Cardiovascular Intensive Care Unit and Associate Professor of Medicine in the Division of Cardiovascular Medicine at Vanderbilt University Medical Center, and an Adjunct Assistant Professor of Medicine at Johns Hopkins University and the University of Louisville.

He serves on the Multi-Ethnic Study of Atherosclerosis (MESA) Project & Publication Committee and the steering committee for the Myocardial Ischemia and Transfusion (MINT) trial.

Dr. DeFilippis’ research is supported by grants from the NIH, Foundations, and Industry.

Disclosures

Dr. DeFilippis reports the following disclosures:
  • NIH R01 Funding
  • Research Grant Ionis Pharmaceutical
  • Consultant Velakor Biotherapeutics, Inc.